<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="28325">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01787916</url>
  </required_header>
  <id_info>
    <org_study_id>2013LIDO</org_study_id>
    <nct_id>NCT01787916</nct_id>
  </id_info>
  <brief_title>52 Week Trial of Liraglutide in Type 1 Diabetes</brief_title>
  <acronym>LIDO</acronym>
  <official_title>Cross-over, Double-blind, Unicentric, 52 Week Trial of Liraglutide in Type 1 Diabetes.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Québec, CHU de Québec</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Québec, CHU de Québec</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To our knowledge, no trial has specifically studied the effect of liraglutide combined with
      a basal/bolus insulin regimen in type 1 diabetes in a cross-over, double-blind, unicentric
      model. Moreover, the potential impact of a glucagon-like peptide-1 agonist on measures of
      abdominal fat (assessed by CT scan), insulin sensitivity (assessed by the gold standard
      euglycemic-hyperinsulinemic clamp) and satiety sensations have not been evaluated in this
      population.

      Hypothesis Overweight participants with type 1 diabetes on liraglutide/insulin treatment
      will present improved glucose control with decreased HbA1c, decreased fasting and mean
      weekly glucose concentrations and glycemic excursions as well as increased insulin
      sensitivity compared to participants on placebo/insulin treatment. Participants with
      liraglutide/insulin treatment will also present improved endothelial function, lower body
      weight, central adipose tissue assessed by CT scan and higher satiety sensations assessed by
      visual analogue scales.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Assessment of changes in glycemic control by HbA1c.</measure>
    <time_frame>Measure changes in HbA1c at 24 and 52 weeks from baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>To investigate the effect of 24 weeks of treatment with liraglutide combined with a basal/bolus insulin regimen in overweight participants with type 1 diabetes on glycemic control as assessed by HbA1c.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of changes in various metabolic measures (composite)</measure>
    <time_frame>Measure changes in the composite at 24 and 52 weeks from baseline</time_frame>
    <safety_issue>No</safety_issue>
    <description>To investigate the effect of 24 weeks of treatment with liraglutide combined with the basal/bolus insulin regimen insulin on glycemic variation, risk of hypoglycemia, glucagon in blood, weight, body mass index (BMI), waist circumference, central adipose tissue area, satiety sensations, the presence of the metabolic syndrome and insulin sensitivity assessed by euglycemia-hyperinsulinemic clamp and estimated glucose disposal rate.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Liraglutide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Liraglutide, s.c., 1.8 mg, die, 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo visually identical to study drug will be given</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide</intervention_name>
    <description>Liraglutide will be compared to placebo for 24 weeks in a cross-over design</description>
    <arm_group_label>Liraglutide</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Liraglutide</other_name>
    <other_name>Victoza</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  type 1 diabetes non smoker BMI superior or equal to 25 diabetes duration superior or
             equal to 5 years

        Exclusion Criteria:

          -  diabetic complication HbA1c superior or equal to 8.5% cancer acute or chronic
             pancreatitis
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stanley John Weisnagel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Québec</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin D'Amours, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Québec</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de Québec</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 17, 2014</lastchanged_date>
  <firstreceived_date>February 4, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>type 1 diabetes</keyword>
  <keyword>overweight</keyword>
  <keyword>insulin</keyword>
  <keyword>liraglutide</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
